Novartis was dealt a blow by a US District Court, which ruled that the company could not be granted a temporary restraining order against Janssen to stop the distribution of Janssen promotional materials that unfavorably compare the safety of a Novartis psoriasis drug, IL-17A inhibitor Cosentyx (secukinumab), to Janssen’s IL-23 inhibitor Tremfya (guselkumab). Find out more about the legal maneuverings behind this industry dispute and what they mean for both companies, in this insightful synopsis from the experts at Pink Sheet.